Ollin Biosciences
PrivateLast Round
Series B
Jun 24, 2026
Est. Valuation
$500M
Total Funding Raised
$430M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Ollin Biosciences is a biopharmaceutical company that develops therapies for vision-threatening ophthalmic diseases such as wet age-related macular degeneration and diabetic macular edema.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ollin Biosciences Comparables
Compare Ollin Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kodiak Sciences Inc. | 79% | |
| VelaVigo | 77% | |
| 4DMT | 77% |
Ollin Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 24, 2026 | ||||
| Series A | Sep 17, 2025 |
Ollin Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B |
| CPP Investments | Series B |
| RA Capital Management | Series B |
| TCG Crossover | Series B |
| ARCH Venture Partners | Series B, Series A |
| Commodore Capital | Series B |
| Monograph Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 29, 2026
Grew 35% QoQ from 20 to 27 employees.
- Jul 25, 2026
Grew 59% QoQ, from 17 to 27 employees.
Ollin Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ollin Biosciences's valuation, stock price, and market status.
Is Ollin Biosciences a public or private company?
Ollin Biosciences is a private company.
What is the current stock price of Ollin Biosciences?
Ollin Biosciences is a private company, so its shares have no public market price. Caplight tracks Ollin Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ollin Biosciences worth (valuation)?
Ollin Biosciences's valuation is estimated at $500.0M based on funding round data.
Can I buy Ollin Biosciences stock?
Ollin Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ollin Biosciences's last funding round?
Ollin Biosciences's most recent funding round was Series B on June 24, 2026.
Who are the main investors in Ollin Biosciences?
Key investors in Ollin Biosciences include TCG Crossover, ARCH Venture Partners, Monograph Capital, ARCH Venture Partners, TCG Crossover.
Will Ollin Biosciences IPO soon?
No public IPO plans have been announced for Ollin Biosciences.
How can I track Ollin Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Ollin Biosciences's shares on secondary markets.